data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Inozyme Pharma
(NASDAQ:INZY)
$4.63
-0.14[-2.94%]
At close: Jul 1
$4.67
0.0400[0.86%]
After Hours: 4:45PM EDT
Day High/Low4.62 - 5.03
52 Week High/Low3.15 - 19.58
Open / Close4.7 / 4.63
Float / Outstanding26.8M / 40.1M
Vol / Avg.138.9K / 320.9K
Mkt Cap185.6M
P/E-
50d Avg. Price4.28
Div / Yield-
Payout Ratio-
EPS-0.71
Total Float26.8M

Inozyme Pharma (NASDAQ:INZY), Quotes and News Summary

Inozyme Pharma (NASDAQ: INZY)

Day High/Low4.62 - 5.03
52 Week High/Low3.15 - 19.58
Open / Close4.7 / 4.63
Float / Outstanding26.8M / 40.1M
Vol / Avg.138.9K / 320.9K
Mkt Cap185.6M
P/E-
50d Avg. Price4.28
Div / Yield-
Payout Ratio-
EPS-0.71
Total Float26.8M
Benzinga - Jun 16, 2022, 7:35AM
Benzinga - May 26, 2022, 8:52AM
Benzinga - May 11, 2022, 6:40AM
Benzinga - May 10, 2022, 8:00AM
Benzinga - Apr 22, 2022, 8:26AM
Benzinga - Apr 21, 2022, 10:19AM
Benzinga - Apr 21, 2022, 8:28AM
Benzinga - Apr 21, 2022, 5:25AM
Benzinga - Apr 20, 2022, 4:25PM
Benzinga - Apr 18, 2022, 4:20PM
Benzinga - Apr 14, 2022, 10:23AM
Benzinga - Apr 14, 2022, 8:17AM
Benzinga - Apr 12, 2022, 10:52AM
Benzinga - Apr 12, 2022, 7:38AM
Benzinga - Apr 4, 2022, 1:13PM
Benzinga - Apr 4, 2022, 1:13PM
Benzinga - Apr 4, 2022, 11:19AM
Benzinga - Apr 4, 2022, 7:34AM
Benzinga - Mar 16, 2022, 9:07AM
Benzinga - Mar 15, 2022, 5:27PM
load more
Sector: Health Care.Industry: Biotechnology
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-10
REV
Q1 2022Est.ActualSurprise
EPS-0.710
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Inozyme Pharma Questions & Answers

Q
How do I buy Inozyme Pharma (INZY) stock?
A

You can purchase shares of Inozyme Pharma (NASDAQ: INZY) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Inozyme Pharma's (INZY) competitors?
Q
What is the target price for Inozyme Pharma (INZY) stock?
A

The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by Jefferies on Thursday, May 26, 2022. The analyst firm set a price target for 5.00 expecting INZY to rise to within 12 months (a possible 7.99% upside). 5 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Inozyme Pharma (INZY)?
A

The stock price for Inozyme Pharma (NASDAQ: INZY) is $4.63 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Inozyme Pharma (INZY) pay a dividend?
A

There are no upcoming dividends for Inozyme Pharma.

Q
When is Inozyme Pharma (NASDAQ:INZY) reporting earnings?
A

Inozyme Pharma’s Q2 earnings are confirmed for Wednesday, August 10, 2022.

Q
Is Inozyme Pharma (INZY) going to split?
A

There is no upcoming split for Inozyme Pharma.

Q
What sector and industry does Inozyme Pharma (INZY) operate in?
A

Inozyme Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.